Page 119 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
PETHEMA
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
• Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive
Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid
Leukemia.
65th ASH Annual Meeting and Exposition 2023 (ASH 2023). 09-12 Dec 2023. San Diego,
CA, USA. Blood. 2023;142(Supplement 1):2864. https://doi.org/10.1182/blood-2023-190128.
Aspas Requena G, Yves Dumas P, Rodríguez Veiga R, Bertoli S, Gil C, Simand C, Ramos-
Ortega FJ, Peterlin P, Serrano J, Birsen R, Bernal Del Castillo T, Tavernier E, Tormo M,
Carre M, García MJ, Contejean A, Riaza Grau R, Orvain C, Pérez-Simón JA, Pérez Santao-
lla E, Veronese L, De Rueda Ciller B, Delabesse E, Gutiérrez A, Mineur A, De La Fuente
Burguera A, Guieze R, Pigneux A, Montesinos P, Recher C, Matínez-Cuadrón D.
• Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative
AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in
the Quiwi Trial.
65th ASH Annual Meeting and Exposition 2023 (ASH 2023). 09-12 Dec 2023. San Diego,
CA, USA. Blood. 2023;142(Supplement 1):6037. https://doi.org/10.1182/blood-2023-180710.
Mosquera Orgueira A, Pérez Encinas M, Díaz Arias JA, Rodríguez Veiga R, Bergua Burgués
JM, Algarra L, Botella C, Pérez Simón JA, Bernal T, Tormo M, Calbacho M, Salamero O,
Serrano J, Noriega V, López López JA, Vives S, Colorado M, López Lorenzo JL, Vidriales
Vicente M, García Boyero R, Olave Rubio MT, Herrera Puente P, Arce O, Barrios García M,
Sayas Lloris MJ, Polo M, Gómez Roncero MI, Barragán E, Ayala R, Chillón C, Calasanz MJ,
Boluda B, Peleteiro Raindo A, Amigo R, Labrador J, Martínez Cuadrón D, Montesinos P.
• Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid
Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry
(EPI-BLAS study).
65th ASH Annual Meeting and Exposition 2023 (ASH 2023). 09-12 Dec 2023. San Diego,
CA, USA. Blood. 2023;142(Supplement 1):4234. https://doi.org/10.1182/blood-2023-190296.
Navarro Vicente I, Lloret Madrid P, Solana-Altabella A, Martínez Sánchez P, Foncillas MA,
Cervero C, Noriega V, Garrastazul Sánchez MP, Alonso Alonso JM, De Rueda Ciller B,
Herrera Puente P, Vives S, Serrano J, Hermosín L, Ramos-Ortega FJ, Bernal T, Lorenzo
Algarra J, Colorado M, García-Boyero R, Bergua Burgués JM, Costilla-Barriga L, Castaño
T, Labrador J, Mena Durán A, Madrigal Toscano MD, Hermosilla-Fernández MM, Couto
C, Pérez Santaolla E, Mariz JM, Casal Marini S, Gil C, Martínez-Cuadrón D, Montesinos P.
• Optimization of a Universal Allogeneic CAR-T Cells Combining CRISPR and Trans-
poson-Based Technologies for Treatment of Acute Myeloid Leukemia.
65th ASH Annual Meeting and Exposition 2023 (ASH 2023). 09-12 Dec 2023. San Diego,
CA, USA. Blood. 2023;142(Supplement 1):3457. https://doi.org/10.1182/blood-2023-189410.
119